Ritonavir is a protease inhibitor with action adjoin Human Immunodeficiency Virus Type 1
(HIV-1). Protease inhibitors block the allotment of HIV alleged protease. HIV-1
protease is an agitator appropriate for the proteolytic break of the viral
polyprotein precursors into the alone anatomic proteins begin in communicable
HIV-1. Ritonavir binds to the protease alive website and inhibits the action of
the enzyme. This inhibition prevents break of the viral polyproteins consistent
in the accumulation of adolescent non-infectious viral particles. Protease
inhibitors are about consistently used in aggregate with at atomic two added
anti-HIV drugs.
Ritonavir
inhibits the HIV viral proteinase agitator which prevents break of the gag-pol
polyprotein, consistent in noninfectious, adolescent viral particles.